Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data from Osaka University, Medical Department provide new insights into cancer vaccines
December 24th, 2008
According to a study from Suita, Japan, "The Wilms' tumor gene WT1 is overexpressed in various kinds of hematopoietic malignancies as well as solid cancers, and this protein has been demonstrated to be an attractive target antigen for cancer immunotherapy. WT1-specific CTL epitopes with a restriction of HLA-A*2402 or HLA-A*0201 have been already identified." "In the present study it has been demonstrated that a 9-mer WT1-derived WT1(187) peptide, which had already been shown to elicit a WT1-specific CTL response with a restriction of HLA-A*0201, can also elicit a CTL response with a restriction of HLA-A*0206. In all three different HLA-A*0206(+) healthy donors examined,...
Source: Vaccine Weekly (2008-12-24)
|
